Flagship Ventures Launches Rubius To Develop Red-Cell Therapeutics
Cambridge, Mass., Dec. 9, 2015/PRNewswire/ — Flagship Ventures, a leading innovation and venture firm focused on healthcare and sustainability, announced it has launched Rubius Therapeutics, to develop functionalized red blood cells for the treatment of autoimmune conditions, metabolic diseases, cancer, and other serious diseases. Flagship has made an initial capital commitment of $25 million to enable Rubius to enter clinical testing of its novel therapeutic modality.